Dusseldorf EUR

BioLineRx Ltd R (YP2A.DU)

Compare

0.1820

+0.0070

(+4.00%)

As of 7:30:37 PM GMT+1. Market Open.

BLRX: Ayrmid Assumes Commercialization Efforts

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT A few days prior to its third quarter earnings report, BioLineRx Ltd. (NASDAQ:BLRX) announced a commercialization agreement with Ayrmid Ltd. and its subsidiary Gamida Cell Ltd. BioLineRx will grant Ayrmid rights to commercialize Aphexda (motixafortide) across all indications except in solid tumors and in all territories

Zacks Small Cap Research 17 days ago

BLRX
BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts

BioLine Rx Ltd (BLRX) reports a significant revenue increase and outlines strategic plans amid operational changes and market challenges.

GuruFocus.com 24 days ago

BLRX
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the third quarter ended September 30, 2024, and provided updates on strategic actions designed to drive shareholder value.

PR Newswire 25 days ago

BLRX
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell

BioLineRx (BLRX) and Ayrmid, the parent company of Gamida Cell (GMDA), announced that the companies entered into a license agreement for motixafortide, BioLineRx’s FDA-approved stem cell mobilization agent indicated in combination with filgrastim for collection and subsequent autologous transplantation in patients with multiple myeloma. Under the terms of the agreement, BioLineRx granted Ayrmid an exclusive license to develop and commercialize Aphexda across all indications, excluding solid tumo

TipRanks 28 days ago

BLRX
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Ayrmid Ltd. ("Ayrmid"), the parent company of Gamida Cell Ltd., today announced that on November 20, 2024, the companies entered into a license agreement for motixafortide (commercially sold in the U.S. as APHEXDA®), BioLineRx's FDA-approved stem cell mobilization agent indicated in combination with filgrastim (G-CSF) for collection and subs

PR Newswire 29 days ago

BLRX
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2024 on Monday, November 25, 2024, before the U.S. markets open.

PR Newswire 30 days ago

BLRX
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that an abstract including the initial results from a Phase 1 clinical trial evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD) was accepted for oral presentation at the 66th American Society of Hematology

PR Newswire last month

BLRX
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Ltd. (NASDAQ/TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for a patent, titled, "COMPOSITION OF BL-8040," which covers the composition of motixafortide (APHEXDA®/BL-8040). The patent strengthens BioLineRx's robust intellectual property (IP) estate and extends its patent protection on motixafortide in th

PR Newswire 2 months ago

BLRX
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced the launch of Mobilization Matters, a digital resource for people with multiple myeloma who are preparing for stem cell collection for an autologous stem cell transplant. Launched on Apheresis Awareness Day, this platform offers patient stories, educational resources, and more to support those undergoing this critical phase of tr

PR Newswire 3 months ago

BLRX
BLRX: On Track for 60% Formulary Placement

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) almost doubled motixafortide product sales sequentially in 2Q:24. The second quarter’s $1.8 million in sales coincided with formulary placement of 37% of targeted centers. Product gross margin was 95%, rising slightly over 1Q:24. The company expects to reach formulary status of 60% of the top 80

Zacks Small Cap Research 3 months ago

BLRX
BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the second quarter ended June 30, 2024, and provided recent corporate and portfolio updates.

PR Newswire 4 months ago

BLRX
BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the second quarter ended June 30, 2024 on Thursday, August 15, 2024, before the U.S. markets open.

PR Newswire 4 months ago

BLRX
BLRX: First Quarter 2024 Results

By John Vandermosten, CFA NASDAQ:BLRX READ THE FULL BLRX RESEARCH REPORT BioLineRx Ltd. (NASDAQ:BLRX) produced a 390% sequential sales increase in its first full quarter of sales in 1Q:24. While it was off of a small base, the quarter’s $924,000 in sales coincided with quarter end formulary placement of around 20%. As of the 1Q:24 report date at the end of May, BioLine had achieved formulary

Zacks Small Cap Research 6 months ago

BLRX
Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025

Making millions through the stock market is only possible in a few ways. Investors need one of these three things: Massive sums of capital to begin with Decades of time and more modest sums of capital More modest sums of capital and a combination of risk and luck We will be talking about the latter today: seven stocks you can buy for $2 that can 10X by 2025. The standard caveat applies here, which says investors should only spend what they are willing to lose. Investing in sub-$2 stocks is very

InvestorPlace 6 months ago

BLRX

ATYR

ADIL
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a multi-center Phase 1 clinical trial sponsored by St. Jude Children's Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD). Investigators in the trial from St. Jude Children's Research

PR Newswire 6 months ago

BLRX
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today reported its unaudited financial results for the first quarter ended March 31, 2024, and provided recent corporate and portfolio updates.

PR Newswire 6 months ago

BLRX
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that an abstract including new data from the single-arm pilot phase of the investigator-initiated, randomized CheMo4METPANC Phase 2 combination clinical trial was accepted for presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois. The CheMo4METP

PR Newswire 6 months ago

BLRX
BioLineRx to Report First Quarter 2024 Results on May 28, 2024

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release its unaudited financial results for the quarter ended March 31, 2024 on Tuesday, May 28, 2024, before the U.S. markets open.

PR Newswire 6 months ago

BLRX
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has received a notification letter from the Nasdaq Stock Market LLC ("Nasdaq"). The letter notifies the Company that it is not in compliance with the minimum bid price requirement set forth in Nasdaq Listing Rules for continued listing on the Nasdaq Capital Market, since the closing bid pric

PR Newswire 6 months ago

BLRX
BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024

BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that new economic model data will be presented on APHEXDA® (motixafortide) for CD34+ hematopoietic stem cell (HSC) mobilization in patients with multiple myeloma at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) – The Professional Society for Health Economics and Outcomes Research – 2024 conference,

PR Newswire 7 months ago

BLRX

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioLineRx Ltd R (YP2A.DU)

BLRX: Ayrmid Assumes Commercialization Efforts

BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts

BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value

BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell

BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

BioLineRx to Report Third Quarter 2024 Results on November 25, 2024

BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024

BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection

BLRX: On Track for 60% Formulary Placement

BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx to Report Second Quarter 2024 Results on August 15, 2024

BLRX: First Quarter 2024 Results

Millionaire Makers: 7 Stocks You Can Buy for $2 That Can 10X by 2025

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)

BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates

BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting

BioLineRx to Report First Quarter 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Announces Poster Presentation on Economic Model Data for APHEXDA® (motixafortide) as part of CD34+ Hematopoietic Stem Cell Mobilization in Patients with Multiple Myeloma at ISPOR 2024